Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12

Intravesical bacillus Calmette-Guerin (BCG) has been used successfully to treat superficial bladder cancer for 3 decades. However, 20–30% of patients will fail initial BCG therapy and 30–50% of patients will develop recurrent tumors within 5 years. Alternative or complementary strategies for the man...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zaharoff, David A., Hoffman, Benjamin S., Hooper, H. Brooks, Benjamin, Compton J., Khurana, Kiranpreet K., Hance, Kenneth W., Rogers, Connie J., Pinto, Peter A., Schlom, Jeffrey, Greiner, John W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788203/
https://ncbi.nlm.nih.gov/pubmed/19638573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-1114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados